• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·000597.SZ
Share

Northeast Pharmaceutical Group Co., Ltd. Stocks

CN¥ 4.87Last Updated 09.10.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

CN¥ 1.01B

CN¥ 4.87
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Northeast Pharmaceutical Group Co., Ltd., established in 1993 and headquartered in Shenyang, China, is a key manufacturer and supplier of active pharmaceutical ingredients (APIs) derived from both chemical synthesis and bio-fermentation. The company also develops and distributes various medicinal and micro-ecological preparation products within China. Its broad portfolio includes nutritional supplements such as Vitamin C and L-Carnitine, as well as specific APIs like fosfomycin and anti-AIDS compounds. Furthermore, it produces chemical goods, including pharmaceutical intermediates and chiral separation reagents. Beyond these, Northeast Pharmaceutical manufactures finished drugs for diverse applications, including digestives, narcotic medicines, and treatments for cardiovascular and cerebrovascular conditions. The group also maintains a significant presence in the medical distribution sector.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value o

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.10.2026 21:01

A Warning Sign for the AI Market: DeepSeek Seeks $12 Billion—Key Details on the IPO as of October 11

11.10.2026 09:19

Twelve people were killed in an attack on the Riyadh airport

10.10.2026 16:01

What's Important in Small-Cap Stocks: Risks Associated with Webull, Levi's Outlook, and Vaxcyte's Success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

10.10.2026 06:47

Moderna hits four-year high as NYT reports U.S. cancer vaccine effort

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026